{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:44:17Z","timestamp":1791902657860,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jval.2025.09.007","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T08:15:34Z","timestamp":1758701734000},"page":"277-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making"],"prefix":"10.1016","volume":"29","author":[{"given":"Jonathan","family":"Mauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Whichello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Hauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Krucien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest H.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Trapali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryanne","family":"Senna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel H.","family":"Zwillich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommi","family":"Tervonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jval.2025.09.007_bib1","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jval.2025.09.007_bib2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","article-title":"Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis","volume":"82","author":"Lee","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jval.2025.09.007_bib3","first-page":"397","article-title":"Epidemiology and burden of alopecia areata: a systematic review","volume":"8","author":"Villasante Fricke","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10387","key":"10.1016\/j.jval.2025.09.007_bib5","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"issue":"10169","key":"10.1016\/j.jval.2025.09.007_bib6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(18)32987-8","article-title":"JAK inhibitors and alopecia areata","volume":"393","author":"Gilhar","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jval.2025.09.007_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.20351","article-title":"Janus kinase inhibitors for alopecia areata: A systematic review and meta-analysis","volume":"6","author":"Liu","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"suppl 1","key":"10.1016\/j.jval.2025.09.007_bib8","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatol (Oxf Engl)"},{"issue":"9","key":"10.1016\/j.jval.2025.09.007_bib11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","article-title":"Discrete choice experiments in health economics: a review of the literature","volume":"32","author":"Clark","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.jval.2025.09.007_bib12","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jval.2016.02.019","article-title":"A framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies","volume":"19","author":"Ho","year":"2016","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2025.09.007_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1634\/theoncologist.2017-0257","article-title":"Individual trade-offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma","volume":"23","author":"Postmus","year":"2018","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.jval.2025.09.007_bib14","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1097\/j.pain.0000000000001952","article-title":"Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations","volume":"161","author":"Smith","year":"2020","journal-title":"Pain"},{"issue":"5","key":"10.1016\/j.jval.2025.09.007_bib15","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/cpt.1447","article-title":"Quantifying preferences in drug benefit-risk decisions","volume":"106","author":"Tervonen","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jval.2025.09.007_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40271-019-00408-4","article-title":"Use of patient preference studies in HTA decision making: a NICE perspective","volume":"13","author":"Bouvy","year":"2020","journal-title":"Patient"},{"issue":"10","key":"10.1016\/j.jval.2025.09.007_bib18","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/jamadermatol.2022.3025","article-title":"Shared decision-making, therapeutic choice, and decisional regret in patients with alopecia areata","volume":"158","author":"Reyes-Hadsall","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.jval.2025.09.007_bib19","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1111\/bcp.15309","article-title":"Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis","volume":"88","author":"Mauer","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jval.2025.09.007_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jval.2022.12.006","article-title":"Quantitative benefit-risk assessment in medical product decision making: a good practices report of an ISPOR task force","volume":"26","author":"Tervonen","year":"2023","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2025.09.007_bib22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/1346-8138.17056","article-title":"Treatment preferences of adults and adolescents with alopecia areata: a discrete choice experiment","volume":"51","author":"Tervonen","year":"2024","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.jval.2025.09.007_bib23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","article-title":"Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program","volume":"25","author":"King","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jval.2025.09.007_bib24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","article-title":"Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force","volume":"19","author":"Hauber","year":"2016","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2025.09.007_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","article-title":"Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force","volume":"16","author":"Johson","year":"2013","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2025.09.007_bib27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2307\/1924536","article-title":"On approximating the statistical properties of elasticities","volume":"68","author":"Krinsky","year":"1986","journal-title":"Rev Econ Stat"},{"issue":"12","key":"10.1016\/j.jval.2025.09.007_bib28","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/sim.4194","article-title":"A stochastic multicriteria model for evidence-based decision making in drug benefit-risk analysis","volume":"30","author":"Tervonen","year":"2011","journal-title":"Stat Med"},{"issue":"7","key":"10.1016\/j.jval.2025.09.007_bib29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1177\/0272989X15587005","article-title":"Applying multiple criteria decision analysis to comparative benefit-risk assessment: choosing among statins in primary prevention","volume":"35","author":"Tervonen","year":"2015","journal-title":"Med Decis Mak"},{"issue":"1-2","key":"10.1016\/j.jval.2025.09.007_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mcda.407","article-title":"A survey on stochastic multicriteria acceptability analysis m ethods","volume":"15","author":"Tervonen","year":"2008","journal-title":"J Multi Criteria Decis Anal"},{"issue":"5","key":"10.1016\/j.jval.2025.09.007_bib31","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jaad.2019.05.086","article-title":"Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis","volume":"88","author":"Okhovat","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jval.2025.09.007_bib32","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","article-title":"Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families","volume":"79","author":"Liu","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jval.2025.09.007_bib33","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","article-title":"Burden of illness in alopecia areata: a cross-sectional online survey study","volume":"20","author":"Mesinkovska","year":"2020","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"1","key":"10.1016\/j.jval.2025.09.007_bib34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","article-title":"Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review","volume":"85","author":"Toussi","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jval.2025.09.007_bib35","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jval.2025.09.007_bib36","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nrd1441","article-title":"A new modality for immunosuppression: targeting the JAK\/STAT pathway","volume":"3","author":"O\u2019Shea","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.jval.2025.09.007_bib37","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ced\/llac106","article-title":"Alopecia areata and risk of common infections: a population-based cohort study","volume":"48","author":"Messenger","year":"2023","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.jval.2025.09.007_bib38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","article-title":"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment","volume":"52","author":"Listing","year":"2013","journal-title":"Rheumatol (Oxf Engl)"},{"issue":"6","key":"10.1016\/j.jval.2025.09.007_bib39","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40257-023-00805-4","article-title":"Comorbid conditions associated with alopecia areata: a systematic review and meta-analysis","volume":"24","author":"Ly","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.jval.2025.09.007_bib40","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/annrheumdis-2020-218419","article-title":"Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden","volume":"80","author":"Molander","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jval.2025.09.007_bib41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s43441-020-00230-3","article-title":"Quantitative benefit-risk assessment: state of the practice within industry","volume":"55","author":"Smith","year":"2021","journal-title":"Ther Innov Regul Sci"},{"issue":"9","key":"10.1016\/j.jval.2025.09.007_bib44","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jval.2019.04.1924","article-title":"Are healthcare choices predictable? The impact of discrete choice experiment designs and models","volume":"22","author":"de Bekker-Grob","year":"2019","journal-title":"Value Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525025641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525025641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:20:57Z","timestamp":1769127657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301525025641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1098301525025641"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2025.09.007","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2025.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}